Pamidronate treatment in patients with malignant osteolytic bone disease and pain: A prospective randomized double-blind trial

Supportive Care in Cancer

Volumn 7, Issue 1, 1999, Pages 21-27

  Koeberle, D ^a   Bacchus, L ^a   Thuerlimann, B ^a   Senn, H J ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

Author keywords

Osteolytic bone disease; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERALIZATION; BONE PAIN; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE NEOPLASMS; DENSITOMETRY, X-RAY; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OSTEOLYSIS; PAIN; PAIN MEASUREMENT; PALLIATIVE CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION;

EID: 0033054489     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050218     Document Type: Article

References (26)

1. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A (1998) In vitro cytoreductive effects on multiple myeloma cells induced by biphosphonates Leukemia 12:220-229
2. Berenson J, Lichtensteig A, Porter L, Dimopoulos M, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simoene J, Reitsma D, Heffernan M, Seaman J, Knight R (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493
3. Body JJ (1992) Metastatic bone disease: clinical and therapeutical aspects. Bone 13:57-62
4. Cascinu S, Graziano F, Alessandroni P, Ligi M, Del Ferro E, Rossi D, Ficarelli R, Catalano G (1998) Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer 6:139-143
5. Coleman RE (1991) Clinical aspect of metastatic bone disease. In: Coleman R, Rubens RD (eds) Metastatic bone disease. Parthenon, Lanes, UK, pp 11-25
6. Coleman RE (1993) Calcium homeostasis, bone metabolism and bisphosphonates. Ther Express 73:1-6
7. Coleman RE, Vinholes J, Abbey ME, Purohit OP (1996) Double-blind randomised trial of pamidronate (Aredia) for the palliative treatment of metastatic bone pain. ASCO Proc 15:528, abs 1706
8. Coleman RE, Purohit OP, Vinholes J (1996) Improved quality of life with high-dose bisphosphonate treatment - the UK experience. In: Possinger K, Ziegler R (eds) Bisphosphonates - improved treatment in malignant and non-malignant indications. (Excerpta oncologica Ciba, vol 5) Ciba-Geigy, Wehr, pp 37-48
9. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trail. Ann Oncol 5 [Suppl7]:41-40
10. Goldhirsch A, Gelber RD, Price KN, et al (1994) Effect of adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-381
11. Goldhirsch A, Gelber RD, Castiglione M, for the Ludwig Breast Cancer Study Group (1988) Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6:89-97
12. Hacking A, Gurdgeon CA, MacNaughton D, Dent DM (1991) Pamidronate (APD) as single infusion monotherapy in the treatment of bone metastases from breast cancer. In: Bijvoet OLM, Lipton A (eds) Osteoclast inhibition in the management of malignancy related bone disorders. Hogrefe & Huber, Lewingston, pp 45-53
13. Hortobagyi G, Theriault R, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone J, Seaman J, Knight R, Heffernan M, Reitsma D (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
14. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
15. Lahtinen R, Laasko M, Palva I, Virrkunen P, Elomaa I (1992) Randomised, placebo-controlled multicenter trial of clodronate in multiple myeloma. Lancet 340:1049-52
16. Lipton A, Glover D, Harvay H, Grabelsky S, Zelenkas K, Macerata R, Seaman J. (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol 5 [Suppl 7]:31-35
17. Morton A, Dodwell DJ, Howell A (1989) Disodium pamidronate APD infusions for bone metastases: clinical trial in patients with breast carcinoma. In: Burkardt P (ed) Disodium pamidronate (APD) in the treatment of malignancy-related disorders. Huber, Toronto, pp 120-133
18. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S (1993) Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65
19. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558
20. Thiébaud D, Leyvraz S, von Fliedner V, Perey L, Cornu P, Thibaud S, Burckard P (1991) Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur J Cancer 27:37-41
21. Thürlimann B (1994) Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects. Ann Oncol 5 [Suppl7]:45-47
22. Thürlimann B, Weisser F, Radziwill A, et al (1993) Pamidronate in patients with malignant osteolytic bone disease and pain: a prospective randomized dose finding study. ASCO Proc 12:4320, abs 1488
23. Thürlimann B, Morant R, Jungi WF, Radziwill A (1994) Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 2:61-65
24. Tyrell CJ (1994) Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trail. Ann Oncol 5 [Suppl 7]:37-40
25. Van Holten-Verzantvoort ATM, Bijvoet OLM, Cleaton FJ (1987) Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate treatment. Lancet 11:983-985
26. World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva